Omeros (NASDAQ:OMER) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why

Omeros Co. (NASDAQ:OMER) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.97 and traded as high as $4.36. Omeros shares last traded at $4.26, with a volume of 189,131 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Friday, August 16th.

Omeros Stock Performance

The firm has a market capitalization of $244.54 million, a price-to-earnings ratio of -1.83 and a beta of 1.48. The business’s 50 day moving average is $3.99 and its 200-day moving average is $3.97.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($1.12) EPS for the quarter. Equities research analysts forecast that Omeros Co. will post -2.9 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Susquehanna Fundamental Investments LLC acquired a new position in Omeros during the 1st quarter valued at $538,000. Vanguard Group Inc. raised its position in shares of Omeros by 2.6% during the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after buying an additional 81,348 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Omeros by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after buying an additional 31,081 shares during the period. AQR Capital Management LLC acquired a new stake in Omeros during the second quarter worth about $105,000. Finally, Oppenheimer & Co. Inc. bought a new position in Omeros during the first quarter valued at about $85,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.